

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under  
37 CFR 1.53(b))

Attorney Docket No.	2879.54-4
First Inventor	Steven W. Dow
Title	Systemic Immune Activation Method Using Non-CpG Nucleic Acids
Express Mail Label No.	EV322529570US

**APPLICATION ELEMENTS**

Commissioner for Patents  
Mail Stop Patent Application  
P. O. Box 1450  
Alexandria, VA 22313-1450

- |   |   |
|---|---|
| <p>1. <input type="checkbox"/> Fee Transmittal Form<br/>(submit an original and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Applicant claims small entity status.<br/>See 37 CFR 1.27</p> <p>3. <input checked="" type="checkbox"/> Specification [73 total pages plus title page]<br/>(preferred Arrangement set forth below)</p> <ul style="list-style-type: none"> <li>- Descriptive title of the Invention</li> <li>- Cross References to Related Applications</li> <li>- Statement Regarding Fed sponsored R&amp;D</li> <li>- Reference to sequence listing, a table, or a computer program listing appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings</li> <li>- Detailed Description</li> <li>- Claim(s) (32 claims)</li> <li>- Abstract of the Disclosure (1 page)</li> </ul> <p>4. <input checked="" type="checkbox"/> Drawing(s) [32 total sheets (Figures 1-33)]</p> <p>5. <input type="checkbox"/> Oath or Declaration [ total pages]</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from prior appl. (37 C.F.R. § 1.63(d))<br/>(for continuation/divisional with Box 18 completed)</p> <p>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b><br/>Signed statement attached deleting<br/>inventor(s) named in prior application,<br/>see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).</p> | <p>6. <input type="checkbox"/> Application Data Sheet. (See 37 CFR 1.76)</p> <p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table<br/>or Computer Program (Appendix)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission<br/>(if applicable, all necessary)</p> <p>a. <input checked="" type="checkbox"/> Computer Readable Form</p> <p>b. <input checked="" type="checkbox"/> Specification Sequence Listing on:</p> <p>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</p> <p>ii. <input checked="" type="checkbox"/> paper</p> <p>c. <input checked="" type="checkbox"/> Statements verifying identity of above copies</p> |
|---|---|

**ACCOMPANYING APPLICATION PARTS**

9. ☐ Assignment Papers (coversheet/document(s))
10. ☐ 37 CFR. 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
11. ☐ English Translation Document
12. ☐ IDS & Form PTO/SB/08A ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
15. ☐ Certified Copy of Priority Document(s)
16. ☐ Nonpublication Request Under 35 USC  
122(b)(2)(B)(i). Applicant must attach form  
PTO/SB/35
17. ☒ Other: Certificate of Mailing by Express Mail

**18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:**


☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Prior application information: Examiner: Group/Art Unit:

FOR CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**19. CORRESPONDENCE ADDRESS**

☒ Customer Number or Bar Code Label **25235** or ☐ Correspondence address below

Name					
Address					
City	State	ZIP			
Country	Telephone	Fax			
Name (Print/Type)	Sarah S. O'Rourke	Registration No.	41,226		
(Signature)			Date	Feb 17, 2004	

22141 U.S. PTO  
10/780294



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Steven W. Dow and Jeffery Fairman

Serial No. NEW

Filed: Herewith

For: SYSTEMIC IMMUNE  
ACTIVATION METHOD USING NON  
CpG NUCLEIC ACIDS

Group Art Unit: Not yet accorded

Examiner: Not yet accorded

CERTIFICATE OF MAILING BY EXPRESS MAIL

MAIL STOP PATENT APPLICATION

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Sir:


The undersigned hereby certifies that the following documents:

1. Utility Patent Application Transmittal;
2. Utility Patent Application (73 pages plus title page);
3. 32 sheets of drawings (Figures 1-33);
4. Sequence Listing;
5. Computer Disk with Sequence Listing;
6. Statement Under 37 CFR § 1.821;
7. Return postcard; and
8. Certificate of Mailing By Express Mail

relating to the above application, were deposited as "Express Mail," Mailing Label No. EV322529570US, with the United States Postal Service, addressed to Mail Stop PATENT APPLICATION, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.


Feb. 17, 2004

Date

  
Mailer

Feb. 17, 2004

Date

  
Sarah S. O'Rourke, Reg. No. 41,226  
HOGAN & HARTSON<sup>LLP</sup>  
1200 17th Street, Suite 1500  
Denver, Colorado 80202  
(720) 406-5385 Tel  
(720) 406-5301 Fax